401565-92-2

Usage

Chemical structure

Piperidine derivative with a BOC protecting group and a substituted amino group with a trifluoromethylphenyl moiety

Functional groups

BOC protecting group, trifluoromethylphenyl moiety, and amino group

Application

Building block in organic synthesis for the preparation of pharmaceutical and agrochemical compounds

Potential use

Precursor for the synthesis of bioactive molecules in medicinal chemistry

Importance

Valuable intermediate in the production of complex organic compounds

Upstream product

• 455-14-1 4-trifluoromethylphenylamine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 128796-39-4 4-trifluoromethylphenylboronic acid 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 

Downstream Products

• 501674-08-4 1-(tert-Butoxycarbonyl)-4-[N-[4-(trifluoromethyl)phenyl]-N-[3-(3,4,5-trimethoxyphenyl)benzyl]amino]piperidine 
• 1350809-13-0 C₁₉H₂₁F₃N₂ 
• 1350809-24-3 C₂₀H₂₀F₃N₃ 
• 1350808-97-7 C₂₄H₂₉F₃N₂O₂ 
• 1350809-09-4 C₂₅H₂₈F₃N₃O₂ 
• 1219625-90-7 tert-butyl 4-(2-bromo-N-(4-(trifluoromethyl)phenyl)acetamido)piperidine-1-carboxylate 

Relevant academic research and scientific papers

NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS

The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds, methods of using the compounds and methods of determining the monoacylglycerol lipase (MAGL) inhibitory activity of the compounds.

NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS

The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

TEAD INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication

A series of CCR5 antagonists were optimized for potent inhibition of R5 HIV-1 replication in peripheral blood mononuclear cells. Compounds that met acceptable ADME criteria, selectivity, human plasma protein binding, potency shift in the presence of α-glycoprotein were evaluated in rat and dog pharmacokinetics.

NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS

The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein Ar1, Ar2, L1, L2, n, R1, R4, X and Y are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Cyclic amine compounds and pharmaceutical composition containing the same

A cyclic amine compound represented by the following general formula (1): wherein, R1, R2 and R3 each independently represent a hydrogen atom or an alkoxy group;W1 and W2 each independently represent N or CH;X represents O, NR4, CONR4 or NR4CO;R4 represents a hydrogen atom, or an alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; andl, m and n each represents a number of 0 or 1, a salt thereof and a hydrate thereof are provided. These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.

ERYTHROPOIETIN PRODUCTION ACCELERATOR

The present invention relates to a preventive or therapeutic agent for pathological conditions caused by reduced production of erythropoietin, or for anemia, or for chronic anemia, renal anemia, aplastic anemia, or pure red cell aplasia, the agent comprising, as an active ingredient, a cyclic amine compound represented by the following formula (1): wherein, ???R1, R2 and R3 each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group; ???W1 and W2 each independently represent N or CH; ???X represents O, NR4, CONR4 or NR4CO; ???R4 each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and ???l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof.

Cyclic amine compounds and pharmaceutical composition containing the same

A cyclic amine compound represented by the following general formula (1): wherein, R1, R2 and R3 each independently represent a hydrogen atom or an alkoxy group; W1 and W2 each independently represent N or CH; X represents O, NR4, CONR4 or NR4CO; R4 represents a hydrogen atom, or an alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; and l, m and n each represents a number of 0 or 1, a salt thereof and a hydrate thereof are provided. These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.